Talimogene Laherparepvec
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 461 publications
The Evolving Role of Intralesional Therapy in In-Transit Melanoma.
Journal: Current oncology (Toronto, Ont.)
Published: April 24, 2026
Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 14, 2026
Oncolytic Viruses in Cancer Therapy: Mechanisms, Challenges, and Emerging Clinical Applications.
Journal: Annales pharmaceutiques francaises
Published: April 08, 2026
Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus.
Journal: Journal of Cancer
Published: March 16, 2026
ASO Visual Abstract: Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers.
Journal: Annals of surgical oncology
Published: March 02, 2026
Outcomes of Talimogene Laherparepvec in Soft Tissue Sarcoma.
Journal: Journal of surgical oncology
Published: February 20, 2026
Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects.
Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: February 12, 2026
Intratumoral oncolytic virotherapy in pancreatic cancer: from feasibility to immune priming.
Journal: Translational gastroenterology and hepatology
Published: February 04, 2026
Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor-Induced Adrenal Insufficiency: A Case Report.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: February 04, 2026
In silico clinical trials of BiTE expression by oncolytic viruses reveal the impact of patient heterogeneity on dosage protocol.
Journal: PLoS computational biology
Published: February 02, 2026
Last Updated: 09/26/2026